Athira Pharma, Inc. (NASDAQ:ATHA) Shares Acquired by Forefront Analytics LLC

Forefront Analytics LLC increased its holdings in Athira Pharma, Inc. (NASDAQ:ATHA) by 126.0% in the second quarter, Holdings Channel.com reports. The firm owned 46,595 shares of the company’s stock after purchasing an additional 25,979 shares during the period. Forefront Analytics LLC’s holdings in Athira Pharma were worth $123,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in the business. Rothschild Investment LLC acquired a new stake in Athira Pharma in the 2nd quarter worth about $34,000. Mirador Capital Partners LP purchased a new position in shares of Athira Pharma during the 1st quarter worth about $57,000. XTX Topco Ltd acquired a new stake in shares of Athira Pharma in the second quarter worth approximately $60,000. American Century Companies Inc. grew its holdings in Athira Pharma by 9.4% in the second quarter. American Century Companies Inc. now owns 38,940 shares of the company’s stock valued at $103,000 after purchasing an additional 3,333 shares during the period. Finally, Renaissance Technologies LLC increased its position in Athira Pharma by 3.5% during the second quarter. Renaissance Technologies LLC now owns 271,488 shares of the company’s stock worth $719,000 after purchasing an additional 9,164 shares during the last quarter. 57.12% of the stock is currently owned by institutional investors and hedge funds.

Athira Pharma Stock Up 6.1 %

ATHA opened at $0.44 on Friday. Athira Pharma, Inc. has a 52-week low of $0.41 and a 52-week high of $4.30. The company has a 50 day moving average of $2.21 and a two-hundred day moving average of $2.39. The company has a market cap of $17.08 million, a P/E ratio of -0.15 and a beta of 2.90.

Athira Pharma (NASDAQ:ATHA) last announced its quarterly earnings results on Thursday, August 1st. The company reported ($0.70) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.05. Research analysts anticipate that Athira Pharma, Inc. will post -2.57 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on ATHA shares. Mizuho lowered shares of Athira Pharma from an “outperform” rating to a “neutral” rating and decreased their price target for the company from $5.00 to $0.50 in a report on Thursday, September 19th. JMP Securities cut Athira Pharma from an “outperform” rating to a “market perform” rating in a report on Wednesday, September 4th. BTIG Research downgraded Athira Pharma from a “buy” rating to a “neutral” rating in a research report on Wednesday, September 4th. Finally, Rodman & Renshaw downgraded Athira Pharma from a “buy” rating to a “neutral” rating in a report on Wednesday, September 4th.

About Athira Pharma

Athira Pharma, Inc, a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies.